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Abstract 
 
In this study, we investigated the regioselective binding mode of steroid molecules 
and structure requirements for steroid molecluse for 16α-hydroxylation by Cytochrome 
P450-2C11.  Docking study by using the homology Cytochrome P450-2C11  indicated 
that 16α-hydroxylation is favored with steroidal molecules possessing the following 
components, 1) a bent A-B ring configuration (5β-reduced), 2) C-3α-hydroxyl group, 3) 
C-17β-acetyl group, and 4) methyl group at both the C-18 and C-19.  These respective 
steroid components requirements such as A-B ring configuration and functional groups 
at C-3 and C-17 were defined as the inhibitory contribution factor.  Overall results by 
rat CYP2C11 revealed that steroidal structure requirements resulted in causing an 
effective inhibition of [³H]progesterone 16α-hydroxylation by the adult male rat liver 
microsome.  As far as docking of homology modeled CYP2C11 against investigated 
steroids is concerned, they are docked at the active site superimposed with flurbiprofen.  
It was also found that the distance between heme iron and C16α-H was between 4 to 6 Å 
and that the related angle was in the range of 180±45°. 
 
 INTRODUCTION 
 
Cytochrome P450 (P450) constitutes a large superfamily of heme-containing 
enzymes capable of oxidizing a variety of substrates, both of endogenous (such as 
steroids) and exogenous (xenobiotics) origins.  Although a variety of P450s are able to 
metabolize a broad range of substrates, the enzymes often exhibit strict regio- and 
stereo-selectivity towards pertinent compounds, such as various steroids 1.  One of the 
most active and versatile P450 is rat CYP2C11, a microsomal P450 subform catalyzing 
more than 90% of steroid 16α-hydroxylations 2-4. It is well known that several 
3-keto-4-ene steroids such as progesterone and testosterone are metabolized in a 
gender-specific and a predominant manners by the adult rat liver microsomes.  In the 
male, these steroids are primarily metabolized into two oxidized (16α-hydroxyl and 6β
-hydroxyl) products mainly by the respective, male-specific cytochrome  P450 subforms, 
CYP2C11 and CYP3A2, while they are primarily metabolized into the 5α-reduced 
products by female predominant 5α-reductase 5. Most of P450 structures reveal that 
the heme group is buried deep within the protein matrix, indicating that residues 
outside of the active site may also be required to guide the substrate into the heme 
pocket by recognizing substrates at the protein surface and/or comprising part of a 
substrate access channel 6.  
In recent years, homology modeling has become an important tool to study the 
P450 function, especially in conjunction with experimental approaches.  A large 
amount of work has been directed to elucidating the substrate-binding sites of various 
P450s, and the understanding of this field is now becoming increasingly important, 
mainly using the two powerful techniques, site-directed mutagenesis and computational 
molecular modeling of the relevant P450s 5-9.  In homology modeling, a 3-dimentional 
(3D) model of the protein is constructed based on its amino acid sequence and on the 
crystal structure of one or more reference proteins.  This mainly involves a sequence 
alignment between the protein and the template(s) 10. 
A challenge remains still quite for the development of a precise 3D-crystal 
structure of CYP2C11.  Therefore, in this study an investigation was carried out on the 
docking mode of 71 different steroid molecules against a computationally homology 
modeled 3D-structure of CYP2C11, so as to see a correlation of the biologically obtained 
results with the AutoDock computational results.   
 
RESULTS AND DISCUSSION 
 
2.1. Homology modeling of CYP2C11 
Homology modeling of CYP2C11 was performed with a cooperation of Swiss-Model 
11, 12.  The amino acid sequence of CYP2C11 structure was used as target protein.  
Various proteins of 500 residues were used as templates, including P450 2C9 with 
warfarin bound, PDB code, log5 13; P450 2C9, PDB code, log2 13; P450 2C9 complexed 
with flurbiprofen bound, PDB code, 1r9o 14; P450 2C8, PDB code, 1pq2 15; P450 
2C5/3LVdH complexed with a bound substrate, 
4-methyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)benzenesulfonamide (DMZ), PDB code, 
1n6b 7; P450 2C5/3LVdH complexed with diclofenac, PDB code, 1nr6 8; P450 2C5, PDB 
code, ldt6 9; P450 2B4 with 4-(4-Chlorophenyl) imidazole bound, PDB code, 1suo 16; P450 
2B4, PDB code, 1po5 16; P450 2A6 with methoxsalen bound, PDB code, 1zll 17; P450 2A6 
with coumarin bound, PDB code, 1z10 [17]; P450 3A4, PDB code, 1tqn 18; P450 3A4 with 
metyrapone bound, PDB code, 1w0g 19; P450 3A4, with PDB code, 1w0e 19; P450 3A4 
with progesterone bound, PDB code, 1w0f [20]; CYP51 with estriol bound, PDB code, 
1x8v 20; CYP51 in ferric low spin state, PDB code, 1h5z [20]; C37L/C151T/C442A-triplet 
mutant of CYP51, PDB code, lu13 21; CYP51 with 4-phenylimidazole bound, PDB code, 
1e9x 21; CYP51 with fluconazole bound, PDB code, 1eal 21.  The pair-wise sequence 
alignments of the target sequence with that of template was carried out and the 
sequence identity of templates with the target sequence is shown in Table 1.  The 
amino acid sequence of the aligned protein templates of chain A of P450 
2C9-flurbiprofen (1r9o), P450 2C9-warfarin (log5), and P450 2C9 (log2) exhibited the 
highest percentage of identity with that of CYP2C11 in the range of 83.5 % , 75.9 %, and 
75.9 %, respectively.  The chain A of the templates of CYP51-estriol (1x8vA), CYP51 
(1h5zA), C37L/C151T/C442A (1u13A), CYP51-4-phenylimidazole (1e9xA), and 
CYP51-fluconazole (1ea1A), whose percentages of identity were 23.3 %, 23.9 %, 23.9 %, 
23.9 %, and 23.9 %, respectively, had been rejected due to their too low similarities with 
the target sequence.   
  
2.2. Docking of representative steroids in the embedded flurbiprofen pocket 
Seventy one different steroid molecules (1-71) ( Table 2) were docked in the 
16α-hydroxylation orientation into the biding site of the homology modeled CYP2C11, 
where the ligand, flurbiprofen (FLP), was embedded.  Affinity orientation between the 
protein and the substrate are predominately hydrophobic.  The side chains of Asn107, 
Ile113, Phe114, Asn204, Phe205, Phe208, Phe237, Thr292, Asp293, Gly296, Ala297, 
Glu300, Thr301, and Leu366 lay within 4 Å of all docked steroid molecules as pointed 
out in Figure 2, where Gly296, Ala297, and Leu366 are hidden for clarity.  Seven of 
these amino acids, namely Phe114, Asn204, Asp293, Gly296, Ala 297, Thr301, and 
Leu366 corresponded identically to the key amino acid residues identified in the earlier 
studies of the binding site of flurbiprofen in CYP2C (PDB code, 1r9o) 14, as cited in PDP 
sum, URL* http://www.ebi.ac.uk/thornton-srv/pdbsum/, accessed on November 12, 
2008. 
The amino acid sequence of the aligned protein templates of chain A of lr9o.pdb, 
log5.pdb, and log2.pdb exhibited the highest percentage of identity with that of 
CYP2C11 in the range of 83.5 %, 75.9 %, and 75.9 %, respectively, as shown in Figure 1 
and Table 1.  The above two findings strongly support the hypothesis that the key 
amino acid residues of CYP2C11 are identical, for the most part, to that of CYP2C9.  
However, this finding must be further verified experimentally.  Figure 2 illustrates the 
ribbon schematic presentations of the homology model of CYP2C11 in sequence 
alignment with the warfarin –bound CYP2C9 (PDB code, log5)13, with CYP2C9 (PDB 
code, log2)13, and with the flurbiprofen-bound CYP2C9 (PDB code, 1r9o).  The details of 
these sequence views are shown in Figure 1, including both the proposed key amino acid 
residues and the different and similar residues of the aligned protein sequences.   
 
2.3. Hydroxylatin of steroids and their docking conformation within the active site  
The ideal conformation of the steroid molecules within their binding site in 
varieties of P450s was proposed by many investigators.  They reported that the 
respective substrates for prokaryotic P450s cam, and eryF are positioned in such a way 
that a substrate is hydroxylated at a distance of 4.5 and 4.8 Å from the heme Fe to the 
hydroxylated atom.  These substrates were also oriented in such a way that the 
hydrogen, which is abstracted during the reaction, be located within 2 Å of the oxygen of 
the oxy-preferryl intermediate 7.  It is also reported that the docked substrates should 
be located with the distance between their oxidation site (C16) and the heme iron being 
6 Å and with the C-H-Fe angle at C16 being 180˚ 22.  The C-H bond in C-H-Fe sequence 
should be perpendicular to the heme surface.  The substrate was usually placed at a 
position equivalent to that of camphor in the P450cam crystallographic structure, which 
gives a distance of about 4.2-4.9 Å between the oxidation sites and the heme iron.  
However, molecular dynamics simulations of camphor-bound P450cam suggests that 
the average distance between the carbon atom, at which hydroxylation takes place, and 
the heme iron is 5.3 Å. 
 
Szklarz, G.D. et al. 1 proposed that for catalysis to occur the following conditions 
must be met; 1) the distance between the hem iron and the carbon, at which the 
hydroxylation takes place, must be 5.6-6 Å to allow room for the active oxygen, which 
results in the carbon to active oxygen distance of 3.9-4.2 Å, and the hydrogen to oxygen 
distance of 2.3-3.1 Å and 2) the angle between the carbon, the hydrogen and the heme 
iron (or active oxygen) should be close to 180˚ (180±45˚) to promote hydrogen bond 
formation.  Therefore, the analysis of the docked results will mainly illustrate the 
above cited issues.  That is, the binding orientation would place a potential site for 
C-16α-hydroxylation within 5-6 Å of the heme iron and the angle between the carbon, 
the hydrogen and the heme iron (or active oxygen) should be as close as possible to 180˚ 
(180±45˚). 
Analysis of the docking results revealed that there were a considerable number of 
conformations flexibilities of the docked substrates oriented in order to meet the above 
mentioned conditions, and it was noticed that many conformations were docked within 
the required distance (4-6 Å), but not by the required angle (180±45˚). 
 
2.4 . The docking energy and mode of binding and the experimentally observed 
inhibitory potency  
The results of inhibitor docking studies and their observed inhibitory potencies against 
[3H]PROG16α-hydroxylation and the number of conformations met with the above 
mentioned condition are shown in Table 2.   
The steroid molecule 3α-hydroxy-5β-pregnan-20-one (33), as shown in Table 2, 
exhibited the highest number of the conformations met with the above mentioned 
conditions with the lowest binding free energy (ΔGb) of 10.42 (-10.09 ) kcal/mol, and the 
minimum inhibition constant (Ki) of 4.03 E-08, i.e., with the highest binding affinity 
(IC40; = 0.24 x 10-7 M) within the CYP2C11 binding site pocket.  The docked 
inhibitor 33, as shown in Figure 3-A, and B was located within 5.7 Å between the 
C16-carbon atom, where the proposed 16α-hydroxylation takes place, and the heme iron, 
and the angle between C16-carbon, C16-α-hydrogen, and the heme iron was 150.6˚.  
The RMSD ( distance in Å, measured between the centeroid of the docked substrate 
and that of the bound ligand, flurbiprofen) was 1.03 Å.  Also the inhibitor 33 showed a 
bent A-B ring configuration within the binding site pocket, as shown in Figure 3-B.  
 
2.5. Docking modes of the other pertinent steroid molecules: 1, 29, 32, 34, 38, and 56  
Docking of other inhibitors, namely 1, 29, 32, 34, 38, and 56, revealed a good 
matching with the above mentioned conditions exhibiting the favorable distance and 
angle of their sites of oxidation and the heme iron.  They are positioned so that their 
C16-carbon atoms be located within 5.73, 5.82, 5.26 , 5.59, 5.53, and 5.51 Å from the 
heme iron, respectively, and their angles between C16-carbon, C16-α-hydrogen, and the 
heme iron were 144.8˚, 148.9˚, 160.9˚ , 146.7˚, 156.1˚, and 153.1˚, respectively.  Their 
corresponding RMSD were 0.92, 1.07, 0.73, 0.71, 0.82, and 4.65 Å, respectively.  Thus, 
it was noticed that these substrates were docked exactly in the same position within the 
binding site pocket and they seem to superimpose with the bound ligand, flurbiprofen, 
as their RMSD distances are quite small with the average of 1.48 Å. Out of the above six 
inhibitors, Figure 3 and 4 illustrate the actual docking mode of inhibitor 32, 33, 34, 38 
and 56. 
 
Inhibitors 1 and 38 with 4-ene A-B ring and inhibitors 29, and 56 with 5α-reduced 
A-B ring are shown in Figure 4 with planar A-B ring configuration, whereas inhibitor 
34 with 5β-reduced A-B ring exhibited bent A-B ring configuration within the binding 
site.   
 
3. Conclusion 
 
Computer simulated automated docking studies were performed using AutoDock 
3.05.  Docking results revealed that there was a variety of conformations of the docked 
inhibitors meeting the confirmation of the reported orientation requirements of steroids 
within their binding sites 1, 7, 15.  The docked inhibitors were shown to be positioned so 
that the site of hydroxylation (C16-carbon) resides within 5-6 Å from the heme iron, 
which is consistent with the distances seen in the case of other P450 substrate complex, 
with the angle between C16-carbon, C16α- hydrogen, and the heme iron being 180±45.0˚.  
It was noticed that steroids were docked exactly overlapped with the flurbiprofen, as 
their average RMSD of 1.98 Å.  Steroid molecule 33 exhibited the lowest binding free 
energy, i.e. the highest affinity within the binding site of CYP2C11, and with the 
highest number of conformations meeting the reported requirements.  This agrees well 
with the biologically observed results; its observed inhibitory potency index against 
[3H]PROG 16α-hydroxylation was 31.46 (IC40;: 3α-hydroxy-5β-pregnan-20-one 33, 0.24 
E-7 M, vs. progesterone 1, 7.55 E-7 M). 
     As a whole, the results of the present docking investigation revealed that many 
amino acid residues responsible for binding of the flurbiprofen-bound CYP2C9 (1r9o), 
were also essential for the interaction between CYP2C11 and inhibitors.  Moreover, 
docking of steroid molecules within the 3-D homology model of CYP2C11 based on that 
of warfarin-bound CYP2C9 (log5), CYP2C9 (log2), and flurbiprofen-bound CYP2C9 
(log5), were in a fair agreement with the observed biological data.  
 
METHODS  
 
4.1. Experimental procedures. 
Materials 
[1,2-3H]Progesterone (PROG) (specific activity, 49.2 Ci/mmol) and [9, 11,12-3H]3
α -OH-5α -P(specific activity, 65.0 Ci/mmol) were obtained from PerkinElmer life 
Sciences, U.S.A. and purified by paper chromatographic system of hexane and 
saturated formamide (H/F).  Unlabeled steroids were purchased from Sigma Chemical 
Company, St. Louis, Mo, U.S.A., and Steraloids, Inc., Wilton, N.H., U.S.A. Whatman 
No.1 filter papers used for paper chromatographies were obtained from Whatman Ltd., 
England.  Other reagents were of analytical grade.   
 
4.2. Preparation of Adult Male Rat Liver Microsomes.   
Approximately 95-day-old male Wistar rats, castrated on the 70th day after birth, 
were used.  The liver microsomes were prepared as previously described 23-25.  The 
experiments were performed according to instrumental guidelines for the care and use 
of laboratory animals.   
 
4.3. [3H]PROG Metabolism by Rat Liver Microsomes – inhibitory effects of various 
unlabeled steroids 
     The metabolism by rat liver microsomes were examined, according to our 
previously described procedure 23-25.  Briefly, the microsomal suspension (400-600 μg of 
protein/2.2 ml, total volume of the reaction mixture) was preincubated with [3H]PROG 
(20 nM) under the absence or presence of an unlabeled steroid (0.01-10 μM) 
at 36˚C for 30 min.  Then NADH (3.16 μM) was added, and the reaction mixture was 
incubated for further 5 min.  After the incubation, two identical samples were mixed 
and extracted with toluene.  The toluene-extractable [3H]PROG metabolites (more 
than 90%) were isolated by various paper chromatographic systems and then identified 
by recrysallization method 26.  Other miscellaneous procedures are described in our 
previous papers 23-25.   
 
4.4. Protein Homology Modeling 
     Since the crystal structure of CYP2C11 is not available, the three dimensional 
(3D) model of CYP2C11 used in the present simulation was constructed based on a 
homology modeling method.  The homology modeling procedure and the sequence 
alignment were performed with the cooperation of Swiss-Model (Swiss-Model version 
36.0003) 11, 12, where comparative modeling techniques were used to prepare homology 
model of CYP 2C11.  Several homologous crystal structures were referred to as 
template structures.  The amino acid sequence for the desired protein was referred to 
as the target.  The crystal template structures were selected from ExPDB template 
database to identify suitable template structures for the comparative modeling.  The 
following templates of 500 sequences residues were downloaded from Brookhaven PDB 
(http://rcsb.org/pdb/):  CYP2C9 with warfarin bound, PDB code, log5; CYP2C9, PDB 
code, log2; CYP2C9 complexed with flurbiprofen bound, PDB code, 1r9o; CYP2C8, PDB 
code, 1pq2; CYP2C5/3LVdH complexed with a bound substrate, 
4-methyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)benzenesulfonamide (DMZ), PDB code, 
1n6b; CYP2C5/3LVdH complexed with diclofenac, PDB code, 1nr6; CYP2C5, PDB code, 
1dt6; CYP2B4 with 4-(4-Chlorophenyl) imidazole bound, PDB code, 1suo; CYP2B4, PDB 
code, 1po5; CYP2A6 with methoxsalen bound, PDB code, lzll; CYP2A6 with coumarin 
bound, PDB code; 1zl0; CYP3A4, PDB code, 1tqn; CYP3A4 with to progesterone bound, 
PDB code, 1w0f; CYP3A4 with metyrapone bound, PDB code, 1w0g; CYP3A4, PDB code, 
1w0e, CYP51 with estriol bound, PDB code, 1x8v; CYP51 in ferric low spin state, PDB 
code, 1h5z; C37L/C151T/C442A-triplet mutant of CYP51, PDB code, 1ul3; CYP51 with 
4-phenylimidazole bound, PDB code, 1e9x; CYP51 with fluconazole bound, PDB code, 
1ea1.  The target sequence was downloaded from the SWISS-PROT database 
(http://us.expasy.org/sprot/), (accession number P08683).  Running pair-wise 
alignments of the target sequence with that of the template were carried out and the 
sequence identity of templates with the target is shown in Table 1.  Those templates of 
1x8vA.pdb, 1h5zA.pdb, lu13A.pdb, 1e9xA.pdb, and 1ea1A.pdb, whose percentages of 
identity were 23.3%, 23.9%, 23.9%, 23.9%, and 23.9%, respectively, had been rejected 
due to their too low similarities with the target sequence.  The sequence alignment was 
followed by adding the missing side chains, adding hydrogens, optimizing loops and 
OXT (nb=1); and the final total energy was -17460.258 KJ/mol, and then hydrogens 
were finally removed.   
 
4.5. Automated Docking 
     Computer simulated automated docking studies were performed using the widely 
distributed molecular docking software, AutoDock 3.05, a grid-based docking program 27, 
which was utilized for the study of binding mode of inhibitors within CYP2C11.  This 
program addresses automatically the flexible docking of the ligands into a known 
protein structure.  In contract, flexibility of the target protein is not taken into account.   
     AutoDock 3.05 scans the active site for low energy binding models and for suitable 
orientations of the probe molecule, using a modified genetic algorism that employs a 
local search (GALS) and precomputed grids for the evaluation of the interaction energy.  
The target homology modeled protein CYP2C11 was separated alone by using DS 
modeling 1.1 software [DS modeling 1.1; Accelrys inc., San Diego, CA (2003)] and 
representative amino acids of the ligand-binding site were selected within 5 Å 
neighborhood surrounding the embedded ligand, flurbiprofen.  A 120 × 120 × 120 Å 
grid size (x, y, z) with a spacing of 0.300 Å centered at - 18.44, 86.67, and 30.89 Å that 
encompassed the active site where the ligand, flurbiprofen, was embedded, was used to 
guide the docked inhibitors.  The results of 250 randomly seeded runs were analyzed 
for each of the docked inhibitors.  The docked inhibitors were assigned to a cluster if 
the atomic coordinates of the docked inhibitors exhibited a root-mean-square deviation 
(RMSD) of less than 0.5 Å difference from each other (RMSD-tolerance of 0.5 Å).  The 
clusters were ranked from the averaged lowest energy obtained for members of the 
cluster to the highest.  The analysis was carried out for the top 10 docking clusters.  
Each of the clusters that exhibited significant negative interaction energies was 
examined by DS modeling program to determine their binding orientations.   
 
4.6. Preparation of small molecules 
ChemDraw ultra 8.0 software [Chemical Structure Drawing Standard; Cambridge 
Soft Corporation, USA(2003)] was used for construction of compounds which were 
converted to 3D structures using Chem 3D ultra 8.0 software [Molecular Modeling and 
Analysis; Cambridge Soft Corporation, USA(2003)] and the constructed 3D structures 
were energetically minimized by using MOPAC with 100 iterations and minimum RMS 
gradient of 0.10.   
 
4.7. Evaluation of docked results 
     DS modeling 1.7 was utilized for the molecular modeling and the evaluation of 
H-bonds in ligand-receptor interaction and for the measurement of RMSD, which was 
computed and expressed in angstrom (Å) as a locational comparison of two relevant 
molecules of interest.  In the actual sense it was measured as a distance between the 
centroids of the docked inhibitor and the bound-ligand, flurbiprofen (FLP).   
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Table 1. Percentage of sequence identity of the pair-wise alignment of various template sequences 
with the target protein sequence (CYP2C11). 
Crystal structures. PDB code % identity Crystal structures. PDB code 
 
% identity 
 
CYP2C9-flurbiprofen 1r9oA 83.46 CYP2A6-methoxsalen 1z11D 52.7 
CYP2C9-warfarin 1og5A 75.9 CYP2A6-coumarin 1z10A 52.6 
CYP2C9 1og2A 75.9 CYP2A6-coumarin 1z10B 52.3 
CYP2C9-warfarin 1og5B 75.9 CYP2A6-coumarin 1z10C 52.7 
CYP2C9 1og2B 75.9 CYP2A6-coumarin 1z10D 52.7 
CYP2C8 1pq2A 74.3 CYP3A4 1tqnA 28.02 
CYP2C8 1pq2B 74.3 CYP3A4-progesterone 1w0fA 30.05 
CYP2C5/3LVdH-DMZ a 1n6b 73.95 CYP3A4-metyrapone 1w0gA 34.25 
CYP2C5/3LVdH-diclofenac 1nr6A 73.95 CYP3A4 1w0eA 28.2 
CYP2C5 1dt6A 71.96 CYP51-Estriol 1x8vA 23.33 
CYP2B4-CPZ b 1suoA 55.1 CYP51 1h5zA 23.9 
CYP2B4 1po5A 54.9 C37L/C151T/C442A-triplet mutant of CYP51 1u13A 23.9 
CYP2A6-methoxsalen 1z11A 52.2 CYP51-4-phenylimidazole 1e9xA 23.9 
CYP2A6-methoxsalen 1z11B 52.6 CYP51-fluconazole 1ea1A 23.9 
CYP2A6-methoxsalen 1z11C 52.7  
a DMZ: 4-Methyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)benzenesulfonamide. 
b CPZ:  4-(4-Chlorophenyl)-imidazole 
Symbols A, B, C, and D are indicative for the amino acid chains involved in sequence alignments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. The inhibitory potency of various steroids on [3H] PROG 16α-hydroxylating activity by  
male rat liver microsomes and their AutoDock results including the binding free energy, the inhibition 
constant, the distance between C16 carbon atom and feme iron and the angle between C16 carbon atom
C16-α hydrogen, and heme Fe iron. 
Steroids 
 
No.               Trivial name 
[3H]PROG16α- 
hydroxylation 
(IC40 x 10-7M)a   
ΔGb 
(kcal/mol ) 
Inhibition 
constant 
(Ki) 
Distance 
(Å) Angle (
o ) 
A. 4-Pregnene steroids 
1. Progesterone 7.55 -10.93 9.76Ee-09 5.73 144.8 
2. 3β-Hydroxyprogesterone 2.55 ---b --- --- --- 
3. 6β-Hydroxyprogesterone 5.1%c --- --- --- --- 
4. 6β-Acetoxyprogesterone 7.40 --- --- --- --- 
5. 11α-Hydroxyprogesterone 4.17% --- --- --- --- 
6. 11α-Acetoxyprogesterone 6.52% --- --- --- --- 
7. 11β-Hydroxyprogesterone 4.93% -11.32 5.04E-09 5.90 139.3 
8. 16α-Hydroxyprogesterone 2.01% --- --- --- --- 
9. 16α-Methylprogesterone 31.3% d -9.97 4.88E-08 5.32 159.1 
10. 18-Hydroxyprogesterone 26.2%  --- --- --- --- 
11. 19-Hydroxyprogesterone 14.0% --- --- --- --- 
12. 19-Norprogesterone 22.4%  --- --- --- --- 
13. 20α-Hydroxyprogesterone 28.5%  --- --- --- --- 
14. 21-Hydroxyprogesterone 3.75% -10.56 1.83E-08 4.73 139.7 
15. 21-Acetoxyprogesterone 0.24% --- --- --- --- 
16. Corticosterone 0.58% -10.54 1.87e-08 4.75 143.6 
B. 5-Pregnene steroids and cholesterol 
17. Pregnenolone 1.42 -11.29 5.32E-09 5.76 139.2 
18. Pregnenolone-3-acetate 8.00 -9.52 1.06E-07 4.92 166.8 
19. Pregnenolone-3-sulfate  1.95 --- --- --- --- 
20. 5-Pregnene-3,20-dione 29.5%  --- --- --- --- 
21. 20α- Hydroxypregnenolone 28.5% -10.61 1.67E-08 5.90 134.8 
22. 21-Hydroxypregnenolone 4.62 -10.86 1.09E-08 5.95 144.8 
23. 21-Acetoxypregnenolone 6.00 -12.20 1.14E-09 4.98 136.3 
24. 21-Sulfatepregnenolone  20.0% -9.69 7.89E-08 4.53 139.7 
25. 5-Pregnen-3β-ol 5.41% --- --- --- --- 
26. Cholesterol 8.60% -9.79 6.65E-08 6.0 159.2 
C. 5α- or 5β-Pregnane steroids 
27. 5α-Pregnan-3,20-dione 7.20 -9.51 1.06E-07   5.86 149.1 
28. 5β-Pregnan-3,20-dione 3.95 -10.45 2.20E-08 4.93 135.0 
29. 3α-Hydroxy-5α-pregnan-20-one 0.62 -10.90 1.03E-08 5.82 148.9 
30. 3α-Acetoxy-5α-pregnan-20-one 4.10 --- --- --- --- 
31. 3α-Sulfate-5α-pregnan-20-one c 2.44% --- --- --- --- 
32. 3β-Hydroxy-5α-pregnan-20-one 2.25 -9.54 1.01E-07 5.26 160.9 
33. 3α-Hydroxy-5β-pregnan-20-one 0.24 -10.09 4.03E-08 5.70 150.6 
34. 3β-Hydroxy-5β-pregnan-20-one 1.70 -10.57 1.78E-08 5.59 146.7 
35. 3α,11β-Dihydroxy-5α-pregnan-20-one 1.50 --- --- --- --- 
36. 3β,16α-Dihydroxy-5α-pregnan-20-one 11.5 --- --- --- --- 
37. 3β-Pregnan-3-one 23.8%  --- --- --- --- 
D. 4-Androstene steroids 
38. 4-Androsten-3,17-dione 10.0 -11.13 6.93E-09 5.53 156.1 
39. 4-Androsten-3-one;17-β-carboxylaic 
acid 
+7.55% e --- --- --- --- 
40. 4-Androsten-3-one;17-β-carboxylaic 
acid methyl ester 8.01 
--- --- --- --- 
41. Testosterone 14.5 -10.02 4.49E-08 4.34 151.5 
42. 17β-Acetoxytestosterone 28.0%  --- --- --- --- 
Table 2. (Continued ). 
Steroids          
            
No.                  Trivial name       
[3H]PROG16α- 
hydroxylation 
(IC40 x 10-7 M)a 
 ΔGb 
(kcal/mol ) 
Inhibition 
constant 
(Ki) 
Distanc
e (Å) 
Angle 
(o ) 
E. 5-Androstene steroids 
43. Dehydroepiandrosterone 6.80 --- --- --- --- 
44. Dehydroepiandrosterone-3-sulfate  28.5% -12.91 3.46E-10 4.06 140.9 
45. 5-Androstenediol 6.40 -10.29 2.88E-08 4.24 160.1 
F. 5α- or 5β−-Androstane steroids 
46. 5α-Androstane 11.7%  -9.69 7.94E-08 5.90 136.4 
47. 5β-Androstane 17.3%  -9.66 8.26E-08 5.94 149.8 
48. 5α-Androstan-3α-ol 10.3 -10.00 4.67E-08 6.0 139.5 
49. 5α-Androstan-3β-ol 6.5 -10.58 1.75E-08 4.0 139.2 
50. 5β-Androstan-3α-ol 5.10 -9.50 1.08E-07 4.55 145.3 
51. 5β-Androstan-3β-ol 1.60 -9.93 5.30E-08 4.49 165.7 
52. 5α-Androstan-17β-ol 27.9%  --- --- --- --- 
53. 5β-Androstan-17β-ol 3.65 -10.22 3.20E-08   5.87 150.6 
54. 5α-Androstan-3,17-dione 6.50 --- --- --- --- 
55. 5β-Androstan-3,17-dione 4.80 -9.98 4.80E-08 5.67 155.2 
56. 3α-Hydroxy-5α-Androstan-17-one 6.35 -9.69 7.89E-08    5.51 153.1 
57. 3β-Hydroxy-5α-Androstan-17-one 4.80 -10.20 3.34E-08 4.69 160.9 
58. 3α-Hydroxy-5β-Androstan-17-one 6.50 -10.00 4.68E-08 5.64 155.4 
59. 3β-Hydroxy-5β-Androstan-17-one 1.85 -10.28 2.92E-08 4.12 158.0 
60. 5α-Dihydrotestosterone 11.5 --- --- --- --- 
61. 5β-Dihydrotestosterone 6.00 -10.23 3.15E-08 5.64 151.1 
62. 5α-Androstan-3α,17β-diol 1.25 --- --- --- --- 
63. 5α-Androstan-3α,17β-diol-17-acetate 3.00 --- --- --- --- 
64. 5α-Androstan-3α,17β-diol-17-sulfate 
c 
28.4% -10.37 2.51E-08   5.45 145.8 
65. 5α-Androstan-3β,17β-diol 11.1 --- --- --- --- 
66. 5β-Androstan-3α,17β-diol 0.69 -10.29 2.86E-08 5.82 150.0 
67. 5β-Androstan-3α-ol-17β-carboxylic 
acid 
3.60 -11.87 2.01E-09 5.0 138.3 
68. 5β-Androstan-3α-ol-17β-carboxylic 
acid methyl ester 
0.43 -10.81 1.20E-08   5.47 156.0 
69. 5β-Androstan-3β,17β-diol 3.20 -10.69 1.46E-08 4.14 148.8 
G.  Estogens 
70. Estradiol-17β 20.7%  --- --- --- --- 
71. Estradiol-17α 11.70% -9.75 7.11E-08 4.15 135.1 
a IC40 value was defined as the molar concentration (x 10-7 M) of an unlabeled steroid causing 40% inhibition  
of [3H]PROG16α-hydroxylation.  
b Docking results are not matched with the required parameters (distance = 4-6Å and angle = 180±45o). 
c, e These imply the mean values of % inhibition c and % increase e , respectively, at 10 μM of the relevant unlabeled 
compound.  d IC40 value  (x 10-7 M) obtained from extrapolation.   
 
 
SEQALI    P08683    30             P PGPTPLPIIG NTLQIYMKDI GQSIKKFSKV YGPIFTLYLG 
SEQALI    1og5A     30             P PGPTPLPVIG NILQIGIKDI SKSLTNLSKV YGPVFTLYFG 
SEQALI    1og2A     30             P PGPTPLPVIG NILQIGIKDI SKSLTNLSKV YGPVFTLYFG 
SEQALI    1r9oA     26         RGKLP PGPTP----L PLQI-GIKDI SKSLTNLSKV YGPVFTLYFG 
   
SEQALI    P08683    71    MKPFVVLHGY EAVKEALVDL GEEFSGRGSF PVSERVNKGL--GVIFSNGM 
SEQALI    1og5A     71    LKPIVVLHGY EAVKEALIDL GEEFSGRGIF PLAERANRGF --GIVFSNGK 
SEQALI    1og2A     71    LKPIVVLHGY EAVKEALIDL GEEFSGRGIF PLAERANRGF --GIVFSNGK 
SEQALI    1r9oA     71    LKPIVVLHGY EAVKEALIDL GEEFSGRGIF PLA--ERANR GFGIVFSNGK 
 
SEQALI    P08683    119   QWKEIRRFSI MTLRTFGMGK RTIEDRIQEE AQCLVEELRK SKGAPFDPTF 
SEQALI    1og5A     119   KWKEIRRFSL MTLRNFGMGK RSIEDRVQEE ARCLVEELRK TKASPCDPTF 
SEQALI    1og2A     119   KWKEIRRFSL MTLRNFGMGK RSIEDRVQEE ARCLVEELRK TKASPCDPTF 
SEQALI    1r9oA     119   KWKEIRRFSL MTLRNFGMGK RSIEDRVQEE ARCLVEELRK TKASPCDPTF 
 
SEQALI    P08683    169   ILGCAPCNVI CSIIFQNRFD YKDPTFLNLM HRFNENFRLF SSPWLQVCNT 
SEQALI    1og5A     169   ILGCAPCNVI CSIIFHKRFD YKDQQFLNLM EKLNENIEIL SSPWIQVYNN 
SEQALI    1og2A     169   ILGCAPCNVI CSIIFHKRFD YKDQQFLNLM EKLNENIEIL SSPWIQVYNN 
SEQALI    1r9oA     169   ILGCAPCNVI CSIIFHKRFD YKDQQFLNLM EKLNENIKIL SSPWIPII-- 
 
SEQALI    P08683    219   FPAIIDYFPG SHNQVLKNFF YIKNYVLEKV KEHQESLDKD NPRDFIDCFL 
SEQALI    1og5A     219   FPALLDYFPG THNKLLKNVA FMKSYILEKV KEHQESMDMN NPQDFIDCFL 
SEQALI    1og2A     219   FPALLDYFPG THNKLLKNVA FMKSYILEKV KEHQESMDMN NPQDFIDCFL 
SEQALI    1r9oA     224   -----DYFPG THNKLLKNVA FMKSYILEKV KEHQESMDMN NPQDFIDCFL 
  
SEQALI    P08683    269   NKMEQEKHNP QSEFTLESLV ATVTDMFGAG TETTSTTLRY GLLLLLKHVD 
SEQALI    1og5A     269   MKMEKEKHNQ PSEFTIESLE NTAVDLFGAG TETTSTTLRY ALLLLLKHPE 
SEQALI    1og2A     269   MKMEKEKHNQ PSEFTIESLE NTAVDLFGAG TETTSTTLRY ALLLLLKHPE 
SEQALI    1r9oA     269   MKMEKEKHNQ PSEFTIESLE NTAVDLFGAG TETTSTTLRY ALLLLLKHPE 
 
SEQALI    P08683    319   VTAKVQEEIE RVIGRNRSPC MKDRSQMPYT DAVVHEIQRY IDLVPTNLPH 
SEQALI    1og5A     319   VTAKVQEEIE RVIGRNRSPC MQDRSHMPYT DAVVHEVQRY IDLLPTSLPH 
SEQALI    1og2A     319   VTAKVQEEIE RVIGRNRSPC MQDRSHMPYT DAVVHEVQRY IDLLPTSLPH 
SEQALI    1r9oA     319   VTAKVQEEIE RVIGRNRSPC MQDRSHMPYT DAVVHEVQRY IDLLPTSLPH 
 
SEQALI    P08683    369   LVTRDIKFRN YFIPKGTNVI VSLSSILHDD KEFPNPEKFD PGHFLDERGN 
SEQALI    1og5A     369   AVTCDIKFRN YLIPKGTTIL ISLTSVLHDN KEFPNPEMFD PHHFLDEGGN 
SEQALI    1og2A     369   AVTCDIKFRN YLIPKGTTIL ISLTSVLHDN KEFPNPEMFD PHHFLDEGGN 
SEQALI    1r9oA     369   AVTCDIKFRN YLIPKGTTIL ISLTSVLHDN KEFPNPEMFD PHHFLDEGGN 
   
SEQALI    P08683    419   FKKSDYFMPF SAGKRICAGE ALARTELFLF FTTILQNFNL KSLVDVKDID 
SEQALI    1og5A     419   FKKSKYFMPF SAGKRICVGE ALAGMELFLF LTSILQNFNL KSLVDPKNLD 
SEQALI    1og2A     419   FKKSKYFMPF SAGKRICVGE ALAGMELFLF LTSILQNFNL KSLVDPKNLD 
SEQALI    1r9oA     419   FKKSKYFMPF SAGKRICVGE ALAGMELFLF LTSILQNFNL KSLVDPKNLD 
 
SEQALI    P08683    469   TTPAISGFGH LPPFYEACFI PV -                             
SEQALI    1og5A     469   TTPVVNGFAS VPPFYQLCFI PV--                             
SEQALI    1og2A     469   TTPVVNGFAS VPPFYQLCFI PV--                             
SEQALI    1r9oA     469   TTPVVNGFAS VPPFYQLCFI PIHH                             
Figure 1. The sequence alignment among CYP2C11(Swiss-prot entry code: P08683), and chain A of  
warfarin-bound CYP2C9 (PDB code:1og5), CYP2C9 (PDB code:1og2) and flurbiprofen-bound CYP2C9 
(PDB code:1r9o). The first 29, 29, 29, and 25 amino acids of these proteins respectively, are not shown 
and were not modeled. Amino acid residues of target protein CYP2C11 are highlighted in bold letters, 
the amino acids of the binding site are indicated by boxed text, the non-matched amino acids are 
underlined, the identical key amino acid residues of 1rgo with that of CYP2C11 are shown in bold Arial 
black letters, and the amino acid sequences of chain B of 1og5 and 1og2 were deleted due to their 
identical amino acid composition to their chain A. 
 Figure 2  The homology modeled structure of CYP2C11 was constructed by a 
cooperation with Swiss-Model11-12.  The amino acid sequence of CYP2C11 in 
white solid ribbon was used as a target protein. It is in sequence alignment with 
the solid ribbon crystal structure of CYP2C9 (PDB code; log5) in cyan with its 
bound ligand SWF (s-warfarin). It is also in sequence alignment with CYP2C 
(PDB code; log2) in violet and with CYP2C9 (PDB code; lr9o) in yellow with its 
bound ligand, FLP (flurbiprofen). Heme and hec Molecules of the aligned protein 
in red ball and stick are shown in an exact superimposed position within the 
  
Figure 3 Docking configurations of inhibitors 32 and 33 (ball and stick in yellow ) 
into the homology modeled CYP2C11 where amino acid residues G296, A297 and 
L366 are hidden for clarity.  A) The relevant amino acid biding sites with the 
inhibitors are shown as wire, colored by atoms, and both inhibitors are docked in a 
superimposed fashion with the embedded substrate flurbiprofen (FLP, wire in blue) 
within RMSD of 0.93 and 0.79 Å respectively. B) Inhibitor 32 exhibits the planar 
A-B ring binding configuration with heme molecule (stick in red), while inhibitor 
33, the bent A-B ring binding configuration. The distance between C16-carbon of 
inhibitor 32 and the heme iron is 5.26 Å with the angle between C16 carbon, 
C16-α hydrogen, and the heme iron being 160.9°, while the formaer of inhibitor 
33, 5.70Å, and the latter, 150.6°. 
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Figure 2: Docking mode of different progesterone derivatives ( inh32, inh33, and inh34) , and androsterone derivatives ( inh38, and inh56) 
within the active site pocket of  FLP( Flurbiprofen ligand , colored by element, ball and stick) in the homlology modeled Cyt P450-2C11. All 
derivatives are shown as yellow, ball and stick within distance of 5-6 Å between C16 and iron atom of heme molecule ( shown as red, stick) 
and angle between 16Cα-hydrogen and iron of heme molecule 180±45o .
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Figure 4  The d i  odes of  different inhibit rs, inh32, inh33, inh34 and inh56 (inhibitor code ), are shown with ball and stick in yellow 
within the binding site pocket of CY 2C11.  The i hibitor code was assigned as a combination term of “inh” plus “steroid number” in Tab e 2. 
The mbedded ligand,  Flurbiprofen (FLP, ball and stick color d by atoms) is bound  inside the pocket of the h mology modeled CYP2C11. 
All i hibitors are docked  within th  distance of 4-6 Å (shown in lines and 3 digit numbers)  between C16 and the iron atom of heme 
molecule (shown as stick in red) and with the angel between the C16 , the 16Cα-hydrogen and the iron of heme molecule being 180 + 45°
(shown in lines and 4 digit numbers). Pertinent amino acids (ASN107, ILE113, PHE114, ASN204 PHE205, PHE237 THR292, ASP293, 
GLY296, ALA297, GLU300, THR301 AND LEU366) lay within 4 Å of all docked steroid molecules and are shown in stick, colored by 
atoms. Hydrogen bond formation is shown in dotted line between the inhibitor and amino the acid residue
